Next-Generation HER2-Directed Combinations

This session will examine first-line treatment strategies for HER2-positive gastroesophageal cancer, comparing established HER2-targeted regimens with emerging next-generation combinations. Faculty will review key clinical data, biomarker considerations, and mechanisms of resistance, while discussing practical factors that influence treatment selection and sequencing. Participants will gain insight into optimizing care in a rapidly evolving landscape. This discussion will explore next-generation HER2-directed combinations in the first-line setting. Faculty will review emerging data on novel agents and combination strategies, focusing on improving response depth and durability. Key considerations include biologic rationale, resistance mechanisms, toxicity, and integration into clinical practice.